Information Statement

Antibiotic Prophylaxis for Bacteremia in Patients with Joint Replacements

This Information Statement was developed as an educational tool based on the opinion of the authors. Readers are encouraged to consider the information presented and reach their own conclusions.

More than 1,000,000 total joint arthroplasties are performed annually in the United States, of which approximately 7 percent are revision procedures. Deep infections of total joint replacements usually result in failure of the initial operation and the need for extensive revision, treatment and cost. Due to the use of perioperative antibiotic prophylaxis and other technical advances, deep infection occurring in the immediate postoperative period resulting from intraoperative contamination has been markedly reduced in the past 20 years.

Bacteremia from a variety of sources can cause hematogenous seeding of bacteria onto joint implants, both in the early postoperative period and for many years following implantation. In addition, bacteremia may occur in the course of normal daily life and concurrently with dental, urologic and other surgical and medical procedures. The analogy of late prosthetic joint infections with infective endocarditis is invalid as the anatomy, blood supply, microorganisms and mechanisms of infection are all different.

It is likely that bacteremia associated with acute infection in the oral cavity, skin, respiratory, gastrointestinal and urogenital systems and/or other sites can and do cause late implant infection. Practitioners should maintain a high index of suspicion for any change or unusual signs and symptoms (e.g. pain, swelling, fever, joint warm to touch) in patients with total joint prostheses. Any patient with an acute prosthetic joint infection should be vigorously treated with elimination of the source of the infection and appropriate therapeutic antibiotics.

Patients with joint replacements who are having invasive procedures or who have other infections are at increased risk of hematogenous seeding of their prosthesis. Antibiotic prophylaxis may be considered, for those patients who have had previous prosthetic joint infections, and for those with other conditions that may predispose the patient to infection (Table 1).

Given the potential adverse outcomes and cost of treating an infected joint replacement, the AAOS recommends that clinicians consider antibiotic prophylaxis for joint replacement patients with one or more of the following risk factors prior to any invasive procedure that may cause bacteremia.

Table 1. Patients at Potential Increased Risk of Hematogenous Total Joint Infection

- All patients with prosthetic joint replacement.
- Immunocompromised/immunosuppressed patients
- Inflammatory arthropathies (e.g.: rheumatoid arthritis, systemic lupus erythematosus)
- Drug-induced immunosuppression
- Radiation-induced immunosuppression
- Patients with co-morbidities (e.g.: diabetes, obesity, HIV, smoking)
- Previous prosthetic joint infections
- Malnourishment
- Hemophilia
- HIV infection
- Insulin-dependent (Type 1) diabetes
- Malignancy
- Megaprostheses

Prophylactic antibiotics prior to any procedure that may cause bacteremia are chosen on the basis of its activity against endogenous flora that would likely to be encountered from any secondary other source of bacteremia, its toxicity, and its cost. In order to prevent bacteremia, an appropriate dose of a prophylactic antibiotic should be given prior to the procedure so that an effective tissue concentration is present at the time of instrumentation or incision in order to protect the patient’s prosthetic joint from a bacteremia induced periprosthetic sepsis. Current prophylactic antibiotic recommendations for these different procedures are listed...
Occasionally, a patient with a joint prosthesis may present to a given clinician with a recommendation from his/her orthopaedic surgeon that is not consistent with these recommendations. This could be due to lack of familiarity with the recommendations or to special considerations about the patient’s medical condition which are not known to either the clinician or orthopaedic surgeon. In this situation, the clinician is encouraged to consult with the orthopaedic surgeon to determine if there are any special considerations that might affect the clinician’s decision on whether or not to pre-medicate, and may wish to share a copy of these recommendations with the physician, if appropriate. After this consultation, the clinician may decide to follow the orthopaedic surgeon’s recommendation, or, if in the clinician’s professional judgment, antibiotic prophylaxis is not indicated, may decide to proceed without antibiotic prophylaxis.

**Table 2.**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Antimicrobial Agent</th>
<th>Dose</th>
<th>Timing</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dental</strong></td>
<td>Cephalexin, cephradine, amoxicillin</td>
<td><strong>2 gm PO</strong></td>
<td>1 hour prior to procedure</td>
<td>Discontinued within 24 hours of the procedure. For most outpatient/office-based procedures a single pre-procedure dose is sufficient.</td>
</tr>
<tr>
<td><strong>Ophthalmic</strong></td>
<td>Gentamicin, tobramycin, ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, ofloxacin, or moxymycin-gramicidin-polymyxin B cefazolin</td>
<td>Multiple drops topically over 2 to 24 hours or 100 mg subconjunctivally</td>
<td>Consult ophthalmologist or pharmacist for dosing regimen</td>
<td></td>
</tr>
<tr>
<td><strong>Orthopaedic†</strong></td>
<td>Cefazolin OR Vancomycin</td>
<td><strong>1-2 g IV</strong></td>
<td>Begin dose 60 minutes prior to procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Vascular</strong></td>
<td>Cefazolin OR Vancomycin</td>
<td><strong>1-2 g IV</strong></td>
<td>Begin dose 60 minutes prior to procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>Cefazolin OR Cefazolin OR Neomycin + erythromycin base (oral) OR metronidazole (oral)</td>
<td><strong>1-2 g IV</strong></td>
<td>Begin dose 60 minutes prior to procedure</td>
<td>Dependent on time of procedure, consult with GI physician and/or pharmacist</td>
</tr>
<tr>
<td><strong>Head and neck</strong></td>
<td>Clindamycin + gentamicin OR cefazolin</td>
<td><strong>600-900 mg IV</strong></td>
<td>Begin dose 60 minutes prior to procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Obstetric and gynecological</strong></td>
<td>Cefoxitin, cefazolin OR Ampicillin/sulbactam</td>
<td><strong>1-2 g IV</strong></td>
<td>Begin dose 60 minutes prior to procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Genitourinary</strong></td>
<td>Ciprofloxacin</td>
<td><strong>500 mg PO or 400 mg IV</strong></td>
<td>1 hour prior to procedure</td>
<td>Begin dose 60 minutes prior to procedure</td>
</tr>
</tbody>
</table>

† If a tourniquet is used the entire dose of antibiotic must be infused prior to its inflation

This statement provides recommendations to supplement practitioners in their clinical judgment regarding antibiotic prophylaxis for patients with a joint prosthesis. It is not intended as the standard of care nor as a substitute for clinical judgment as it is impossible to make recommendations for all conceivable clinical situations in which bacteremias may occur. The treating clinician is ultimately responsible for making treatment recommendations for his/her patients based on the clinician’s professional judgment.

Any perceived potential benefit of antibiotic prophylaxis must be weighed against the known risks of antibiotic toxicity, allergy, and development, selection and transmission of microbial resistance. Practitioners must exercise their own clinical judgment in
determining whether or not antibiotic prophylaxis is appropriate.

References:

1. Number of Patients, Number of Procedures, Average Patient Age, Average Length of Stay - National Hospital Discharge Survey 1998-2005. Data obtained from: U.S. Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Health Statistics.


5. Guntheroth WG: How important are dental procedures as a cause of infective endocarditis? Amer J Cardiol 1984;54:797-801.


February 2009 American Academy of Orthopaedic Surgeons

This material may not be modified without the express written permission of the American Academy of Orthopaedic Surgeons.

Information Statement 1033

For additional information, contact the Public Relations Department at 847-384-4031.